Seed Therapeutics, a biotech firm specializing in molecular glue degraders, has partnered with Eisai, a pharmaceutical company, in a deal worth over USD 1.5 billion. The collaboration aims to discover, develop, and commercialize novel molecular glue degraders for undisclosed neurodegeneration and oncology targets. Seed Therapeutics will focus on preclinical discovery, while Eisai will contribute its neurodegeneration and cancer research expertise.
As part of the agreement, Eisai will have exclusive rights to develop and commercialize compounds from the collaboration. Seed Therapeutics will receive upfront and milestone payments of up to USD 1.5 billion, plus tiered royalties.
Concurrently, Seed Therapeutics has launched a Series A-3 financing round, led by Eisai and with a first close of USD 24 million, to accelerate its clinical development programs and expand its targeted protein degradation platform.
Seed Therapeutics is a biotechnology company specializing in developing novel therapeutics using proprietary molecular glue technology. The company primarily focuses on creating treatments for severe diseases, including cancer, neurodegeneration, and infectious diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.